Posted in News
Preparations of ivacaftor (Kalydeco®) have now been mapped to the dm+d following following confirmation from the NHSE.
The virtual medicinal product (VMP) is included in a number of Tags so the mapping of individual drug lines from Trusts will now be seen. The Tags affected include those for NHSE Mucolytics, High Cost Drugs List 2017-19, Non-PbR and Passthrough Costs (current).
It is very likely Trusts will see an increase in reported spends